1. ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, Rational Pharmaceutical Management Plus

2. Date of Data Collection
Source of Information
Country
Date of Data Collection
Population
Cote d'Ivoire
Sept 2005
Adults
Ethiopia
July 2005
Haiti
December ‘04 to July 2005
Adults and Pediatrics
Kenya
Namibia
March 2005
Rwanda
August 2005
Zambia

3. Limitations
Data Collected from selected countries may not be representative of total population treated in countries and may include non-PEPFAR supported patients
Data not available on rate of switch from 1st- to 2nd-line regimens
All reported regimens included in analysis of 1st-line ARV distribution
All regimens, except for WHO 1st-line regimens, considered in analysis of 2nd-line ARV distribution
Ritonavir was excluded in analysis
Some pediatric regimens may have been counted as adults
Pediatric regimens not organized by formulation taken-data not available

4. Summary of Data Collected
Total number of patients: 77,378
Adult patients: 71,550
Pediatric patients: 5,828
Total number of adult regimens: 76
Total number of pediatric regimens: 31

5. Percentage of Adult Patients on WHO 1st-line Regimens

6. Percentage of Pediatric Patients on WHO 1st-line Regimens

7. Percentage of Adult ART Regimens with NRTIs only

8. Percentage of Pediatric ART Regimens with NRTIs only

9. Distribution of ARVs in 1st-line Regimens
% in Adult Regimens
% in Pediatric Regimens
3TC
97.8%
98.7%
D4T
71.5%
43.8%
ZDV
27.7%
55.7%
TDF
0.29% —
EFV
26.3%
27.1%
NVP
70.6%
69%
ddI
2.4%
0.84%
ABC
0.71%
1.37%
PIs
2.61%
2.99%
LPV/r
0.85%
2.95%
NFV
0.69%
0.02%
IDV
1.06%
SQV/r
0.01%

10. Distribution of ARVs in 2nd-line Regimens
% in Adult 2nd-line Regimens
% in Pediatric 2nd-line Regimens
ddI
51.2%
17.8%
ABC
15%
29%
TDF
6.26% —
PIs
55.7%
63%
IDV
22.52%
0.36%
LPV/r
18.17%
62.32%
NFV
14.69%
SQV/r
0.15%
(ZDV, D4T, 3TC, EFV and NVP have been excluded)